- BioCryst Pharmaceuticals ( NASDAQ: BCRX ) is scheduled to announce Q2 earnings results on Thursday, August 4th, before market open.
- The consensus EPS Estimate is -$0.35 (-45.8% Y/Y) and the consensus Revenue Estimate is $63.83M (+27.7% Y/Y).
- Over the last 1 year, BCRX has beaten EPS estimates 25% of the time and has beaten revenue estimates 50% of the time.
- Over the last 3 months, EPS estimates have seen 4 upward revisions and 3 downward. Revenue estimates have seen 5 upward revisions and 5 downward.
For further details see:
BioCryst Pharmaceuticals Q2 2022 Earnings Preview